AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) dropped 0.7% on Friday . The company traded as low as $24.51 and last traded at $25.19, with a volume of 851,747 shares trading hands. The stock had previously closed at $25.37.

AMAG has been the topic of a number of research reports. Leerink Swann reaffirmed an “outperform” rating on shares of AMAG Pharmaceuticals in a research note on Saturday, April 16th. Jefferies Group reaffirmed a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Wednesday, June 8th. Robert W. Baird cut their target price on shares of AMAG Pharmaceuticals from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Monday, March 28th. Deutsche Bank AG cut their target price on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating on the stock in a research note on Monday, May 9th. Finally, Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 18th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $38.20.

The firm has a market cap of $871.02 million and a price-to-earnings ratio of 84.25. The company has a 50 day moving average of $22.56 and a 200-day moving average of $23.72.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.11 by $0.17. The firm had revenue of $117.60 million for the quarter, compared to analyst estimates of $124.83 million. During the same quarter in the prior year, the company posted $1.17 earnings per share. The company’s revenue for the quarter was up 41.9% on a year-over-year basis. On average, equities research analysts expect that AMAG Pharmaceuticals Inc. will post $5.20 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in AMAG. Dimensional Fund Advisors LP increased its stake in shares of AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock valued at $12,010,000 after buying an additional 8,435 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at $3,774,000. LSV Asset Management increased its stake in shares of AMAG Pharmaceuticals by 19.9% in the fourth quarter. LSV Asset Management now owns 93,842 shares of the specialty pharmaceutical company’s stock valued at $2,833,000 after buying an additional 15,600 shares in the last quarter. Bank of Montreal Can increased its stake in shares of AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock valued at $1,893,000 after buying an additional 3,903 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.